Enzo Biochem, Inc. – Contract (May 30th, 2007)
EXHIBIT 2.1 ================================================================================ STOCK PURCHASE AGREEMENT BY AND AMONG ENZO LIFE SCIENCES, INC. AXXORA LIFE SCIENCES, INC. AND THE STOCKHOLDERS, OPTIONHOLDERS AND WARRANTHOLDERS NAMED ON SCHEDULE I HERETO MAY 29, 2007 ================================================================================ TABLE OF CONTENTS
Genaissance Pharmaceuticals – Confidential Separation Agreement and General Release (August 16th, 2005)
This Confidential Separation Agreement and General Release (Agreement) between Carl Balezentis, Ph.D., of 54 Pipers Meadow Street The Woodlands, TX 77382 (Employee), and Genaissance Pharmaceuticals, Inc., with a principal place of business at Five Science Park, New Haven, CT 06511 (Genaissance), sets forth the terms and conditions of the end of Employees employment with Genaissance and any severance or other benefits to be paid to Employee in connection with his separation from Genaissance and/or termination of employment. Employee and Genaissance agree to the following terms and conditions:
Genaissance Pharmaceuticals – Note and Warrant Purchase Agreement (April 27th, 2005)
THIS NOTE AND WARRANT PURCHASE AGREEMENT (this Agreement) is made and entered into as of April 21, 2005, by and among Genaissance Pharmaceuticals, Inc., a Delaware corporation (Genaissance) and Lark Technologies, Inc., a Delaware corporation (Lark, and together with Genaissance, the Co-Borrowers), and Xmark Opportunity Fund, Ltd., a Cayman Islands exempted company, Xmark Opportunity Fund, L.P., a Delaware limited partnership, and Xmark JV Investment Partners, LLC, a Delaware limited liability company (together, the Purchasers and each, a Purchaser).
Genaissance Pharmaceuticals – Contract (March 15th, 2005)
Genaissance Pharmaceuticals – Contract (February 12th, 2004)
EXHIBIT 10.58 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT ("Agreement") made and entered into as of December 18, 2003 and to take effect, if at all, upon the date of the Closing (as defined hereafter) (the "Effective Date"), by and between GENAISSANCE PHARMACEUTICALS, INC. (the "Corporation"), a Delaware corporation with its principal office at 5 Science Park, New Haven, Connecticut, 06511, and CARL BALEZENTIS ("Executive"), an individual who resides at 54 Pipers Meadow Street, The Woodlands, Texas 77382. WHEREAS, the Corporation and Lark Technologies, Inc. ("Lark") have entered into agreements pursuant to which Lark would become a wholly-owned subsidiary of the Corporation if and when the transactions contemplated by such agreements take final effect (the "Closing "); and WHEREAS, the Corporation and Executive desire to enter into this Agreement to set forth the terms and conditions of their employment relationship, commencing as of the E
Genaissance Pharmaceuticals – Agreement and Plan of Merger (December 22nd, 2003)
THIS AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of December 18, 2003, is by and among Genaissance Pharmaceuticals, Inc., a Delaware corporation (the "Buyer"), Brown Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of the Buyer (the "Transitory Subsidiary"), and Lark Technologies, Inc., a Delaware corporation, including any foreign branch, division or operating unit (collectively, the "Company").